Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.
Immunocore, a UK-based bispecific immunotherapy developer backed by pharmaceutical firms Eli Lilly and WuXi AppTec, has floated on the Nasdaq Global Select Market having raised over $258m in its initial public offering. The offering consisted of approximately 9.94 million American Depositary Shares priced at $26.00 each, above the offering’s $23 to $25 range. Immunocore concurrently…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.